{
  "case_id": "EI16-24189",
  "year": 2016,
  "patient_info": {
    "age_range": "51 to 64",
    "gender": "Female"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [
    "Idiopathic Thrombocytopenic Purpura",
    "Myelodysplastic Syndromes"
  ],
  "complications": [
    "ITP and MDS complications"
  ],
  "symptoms": [],
  "treatment_category": "Diag Imag & Screen",
  "treatment_subcategory": "Lab Work",
  "treatments_requested": [
    {
      "name": "Gene Testing",
      "drug_type": null,
      "procedure_type": "diagnostic",
      "is_procedure": true,
      "other_or_notes": "Molecular gene testing to determine if MDS is primary or secondary"
    }
  ],
  "treatments_tried_but_failed": [
    {
      "name": "Standard Testing",
      "drug_type": null,
      "procedure_type": "diagnostic",
      "is_procedure": true,
      "other_or_notes": "Did not clarify if MDS is primary or secondary"
    }
  ],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [],
  "is_denial_upheld": false,
  "issues_considered": [
    "medical_necessity",
    "plan_coverage"
  ],
  "other_issues": null,
  "guidelines_support": true,
  "guidelines_not_support": null,
  "guidelines_details": "NCCN guidelines recommend molecular gene testing in appropriate cases.",
  "soc_support": null,
  "soc_not_support": null,
  "soc_details": null,
  "study_support": null,
  "study_details": [],
  "key_questions": [
    "medical_necessity",
    "plan_coverage"
  ],
  "expedited": false,
  "rationale": "The gene panel testing was likely to be more beneficial for treatment of the patient\u2019s medical condition than any available standard therapy. The Health Plan\u2019s denial should be overturned.",
  "reviewer_credentials": "Physician reviewers are board certified in internal medicine with sub-specialty certification in medical oncology and are actively practicing."
}